PERIOSTIN is a potential marker for breast cancer progression

During Breast Cancer Awareness Month, let´s share insights on emerging biomarkers such as PERIOSTIN that offer potential for improved diagnosis, prognosis, and personalized therapy.

PERIOSTIN is a potential marker for breast cancer progression

 Periostin is a matricellular protein that plays a significant role in the progression of breast cancer. Several studies have demonstrated that Periostin is overexpressed in breast cancer tissues compared to normal breast tissue (1, 2). In addition, breast tumor progression has been shown to be accompanied by increased Periostin expression; researchers could show that elevated Periostin expression in epithelial cells was linked to decreased disease-free survival and overall survival (3). These findings suggest that Periostin plays a significant role in breast tumor progression.

 

High circulating Periostin levels are associated with aggressive breast cancer subtypes and poorer patient prognosis

Periostin is involved in various processes such as tumor growth, invasion, metastasis, and the modulation of the tumor microenvironment (4). High serum Periostin levels have been associated with more aggressive breast cancer subtypes and poorer patient prognosis (5). Periostin promotes tumor cell survival, supports angiogenesis, and facilitates the remodeling of the extracellular matrix, thereby aiding cancer cell dissemination (5).

 

Periostin significantly impacts cancer progression and treatment outcomes

Periostin plays vital roles in tumor development, metastasis, resistance to chemotherapy, and shaping the tumor microenvironment (6). In addition, Periostin contributes to chemotherapy resistance by creating a protective niche for cancer cells (6). In a recent study researchers explored the relationship between Periostin and the tumor microenvironment, highlighting its potential as a promising prognostic biomarker and therapeutic target for addressing tumor progression and chemoresistance (7). In a further study researchers aimed to identify proteins that are overexpressed in tumors with extensive stroma within immune-excluded triple-negative breast cancer, revealing a link between Periostin and elevated tumor stroma along with immune exclusion in triple-negative breast cancer (8).

Periostin can reliably be measured in biological fluids with a conventional ELISA assay

Periostin ELISA Assay Highlights (Cat. No. BI-20433)

• Small sample volume – 10 µl / well
• Reliable – full validation package
• Easy – 7 standards and 2 controls included
• Trusted – widely cited 

 

Download our Periostin Flyer here

 

 

Literature

1. Expression of periostin in human breast cancer. Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D’Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, Di Loreto C. J Clin Pathol. 2008 Apr;61(4):494-8. doi: 10.1136/jcp.2007.052506. Epub 2007 Oct 15. PMID: 17938160.
2. The expression analysis of periostin in human breast cancer. Zhang Y, Zhang G, Li J, Tao Q, Tang W. J Surg Res. 2010 May 1;160(1):102-6. doi: 10.1016/j.jss.2008.12.042. Epub 2009 Feb 27. PMID: 19524268.
3. Epithelial periostin expression is correlated with poor survival in patients with invasive breast carcinoma. Kim GE, Lee JS, Park MH, Yoon JH. PLoS One. 2017 Nov 21;12(11):e0187635. doi: 10.1371/journal.pone.0187635. PMID: 29161296; PMCID: PMC5697858.
4. Periostin: biology and function in cancer. Dorafshan S, Razmi M, Safaei S, Gentilin E, Madjd Z, Ghods R. Cancer Cell Int. 2022 Oct 12;22(1):315. doi: 10.1186/s12935-022-02714-8. PMID: 36224629; PMCID: PMC9555118.
5. High serum levels of periostin are associated with a poor survival in breast cancer. Rachner TD, Göbel A, Hoffmann O, Erdmann K, Kasimir-Bauer S, Breining D, Kimmig R, Hofbauer LC, Bittner AK. Breast Cancer Res Treat. 2020 Apr;180(2):515-524. doi: 10.1007/s10549-020-05570-0. Epub 2020 Feb 10. PMID: 32040688.
6. The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response. De Oliveira Macena Y, Cezar MEN, Lira CBF, De Oliveira LBDM, Almeida TN, Costa ADAV, De Araujo BMD, de Almeida Junior D, Dantas HM, De Mélo EC, de Araújo ST, de França Júnior RR, Dos Santos Lemos Gurgel MA, de Carvalho Fraga CA. Cancer Metastasis Rev. 2024 Nov 30;44(1):11. doi: 10.1007/s10555-024-10233-3. PMID: 39614015.
7. The association between periostin and tumor microenvironment: a promising cancer prognostic biomarker and therapeutic target to combat tumor progression and chemoresistance. Nabi-Afjadi M, Farzam F, Soltani S, Golestani N, Asl SS, Aziziyan F, Zalpoor H, Ghasemi F, Dabirmanesh B, Khajeh K. Cancer Cell Int. 2025 Sep 3;25(1):320. doi: 10.1186/s12935-025-03959-9. PMID: 40903761; PMCID: PMC12406393.